News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genentech (RHHBY) Grabs Breakthrough Approval for Chronic Leukemia Drug Gazyva


11/1/2013 9:39:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The FDA today approved its first “breakthrough” medicine—Genentech’s Gazyva™ (obinutuzumab or GA101), in combination with chlorambucil chemotherapy for people with previously untreated chronic lymphocytic leukemia (CLL). The Roche subsidiary trumpeted the approval as FDA’s fifth for a new drug developed by the company in the past three years. Gazyva is the first approved drug to have been designated a Breakthrough Therapy by the FDA.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
Genentech
 
 
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES